Joint Formulary & PAD

Alemtuzumab - Multiple sclerosis

You are here : Home > Formulary Search > Alemtuzumab - Multiple sclerosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NHSE
NICE
SPC
Restrictions / Comments :
Important

ASPH are the only Surrey Heartlands Trust commissioned to provide this.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Alemtuzumab
Indication :
Multiple sclerosis
Group Name :
Keywords :
MS, monoclonal antibody, anti-lymphocyte
Brand Names Include :
Lemtrada
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

02 Apr 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Alemtuzumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Multiple sclerosis.